RESEARCH MONOGRAPH · KDC-MN-258

Clonidine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

84/100

Decades-old alpha-2 agonist still doing real work in opioid withdrawal, ADHD, and autonomic research

Clonidine is one of those compounds that nobody would design today but that has aged surprisingly well. Boehringer Ingelheim's nasal decongestant program in the early 60s accidentally produced a centrally-acting alpha-2 adrenergic agonist with hypotensive effects, and the rest is sixty years of off-label clinical drift. Originally a hypertension drug, now used across opioid withdrawal management, ADHD adjunct, anesthesia adjunct, hot flashes, Tourette's, and substance use research.

The mechanism is well-mapped. Agonism at central alpha-2 receptors in the locus coeruleus reduces noradrenergic outflow, which is the proximate cause of the hypotensive and sedative effects. The same pathway is why clonidine works in opioid withdrawal: the rebound noradrenergic storm during withdrawal is exactly what alpha-2 agonism damps. Imidazoline I1 receptor activity is also real but less clinically dominant than the alpha-2 effects, despite some authors in the 90s overplaying that angle.

What we like as a research tool is the cleanness of the central noradrenergic probe. If you want to ask questions about locus coeruleus output, sympathetic tone, or the autonomic component of stress responses, clonidine gives you a well-characterized lever. The growth hormone response to clonidine is a classic endocrine probe of alpha-2 function that still appears in modern research.

What we dont like is the alpha-2A versus alpha-2B versus alpha-2C selectivity is mediocre. Clonidine hits all three, which makes circuit-level dissociations harder than they should be. For that work, guanfacine (more alpha-2A selective) or dexmedetomidine (different selectivity profile and parenteral) is often the better tool.

The reliability is high for what it's used for. Rebound hypertension on abrupt discontinuation is a real phenomenon that anyone working with chronic dosing models needs to design around. The bradycardia is dose-dependent and predictable.

Sourcing is excellent. Off-patent for decades, pharmacopoeial quality widely available globally, the hydrochloride is the dominant salt. Transdermal patch formulations are a different beast but the research-grade powder is standard.

Workhorse with multiple second lives. Reliability is solid, mechanism is textbook, and the central-versus-peripheral noradrenergic dissection that clonidine enables is still useful. Underappreciated by anyone outside cardiovascular and substance-use research.

Evidence: 90
Mechanism: 88
Reliability: 85
Safety: 80
Sourcing: 92
Value: 90
Signal: 70
Staying power: 80

Plain-language summary Intrigue 60 / 100

Clonidine is a 1960s blood-pressure drug (sold as Catapres) that turned out to be unexpectedly versatile. It works by activating alpha-2 adrenergic receptors in the brainstem, dampening the sympathetic nervous system, the body's stress response. That single mechanism explains why it lowers blood pressure, blunts opioid withdrawal symptoms, calms tics in Tourette syndrome, and reduces hyperactivity in ADHD (often as a non-stimulant alternative or add-on to stimulants in children). It is also used to manage hot flashes and as a sedating premedication. The drug is cheap, generic, and well-characterized, with sedation and rebound hypertension on abrupt discontinuation as the main downsides. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Central alpha-2 adrenergic agonist

An imidazoline alpha-2 adrenergic receptor agonist; an antihypertensive repurposed for ADHD, opioid withdrawal, and Tourette syndrome.

Abstract

Clonidine (N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; CAS 4205-90-7; molecular formula C9H9Cl2N3; molecular weight 230.10) is an imidazoline alpha-2 adrenergic agonist developed at Boehringer Ingelheim in the 1960s and approved by the FDA in 1974 under the trade name Catapres. The compound activates presynaptic alpha-2A adrenergic autoreceptors in the locus coeruleus, reducing central noradrenergic outflow and producing centrally mediated reductions in sympathetic tone, blood pressure, and heart rate. Secondary imidazoline I1 receptor activity contributes to the antihypertensive effect. Plasma half-life is 12 to 16 hours; renal excretion is the principal clearance pathway. Approved indications include hypertension, ADHD (extended-release Kapvay), opioid withdrawal, and Tourette syndrome; off-label use in insomnia, hot flashes, and PTSD-associated hyperarousal. Rebound hypertension on abrupt discontinuation is a characteristic adverse effect. The compound is widely used in academic neuroscience as the prototype alpha-2 agonist for studies of noradrenergic regulation.

Mechanism of action

Central alpha-2A adrenergic agonism; reduces locus coeruleus noradrenergic outflow. Secondary imidazoline I1 receptor activity.

Reported research dose ranges

Clinical 0.1 to 0.6 mg in the published literature. Rodent studies 0.01 to 0.5 mg/kg.

References

Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology 1991.
Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001.
Connor DF, et al. Pharmacological treatment of ADHD: a review of the evidence. Curr Opin Pediatr 2008.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-258

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Clonidine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs